Your browser is no longer supported. Please, upgrade your browser.
Settings
DRRX [NASD]
DURECT Corporation
Index- P/E- EPS (ttm)-0.17 Insider Own1.43% Shs Outstand227.43M Perf Week8.26%
Market Cap279.80M Forward P/E- EPS next Y-0.18 Insider Trans-1.73% Shs Float224.24M Perf Month1.55%
Income-37.40M PEG- EPS next Q-0.05 Inst Own53.10% Short Float3.36% Perf Quarter-22.94%
Sales8.50M P/S32.92 EPS this Y40.10% Inst Trans-1.13% Short Ratio14.70 Perf Half Y-41.52%
Book/sh0.32 P/B4.09 EPS next Y0.00% ROA- Target Price- Perf Year-25.57%
Cash/sh0.41 P/C3.16 EPS next 5Y15.00% ROE- 52W Range1.20 - 2.95 Perf YTD-36.71%
Dividend- P/FCF- EPS past 5Y17.80% ROI-20.70% 52W High-55.55% Beta1.25
Dividend %- Quick Ratio11.40 Sales past 5Y9.50% Gross Margin82.80% 52W Low9.17% ATR0.07
Employees79 Current Ratio11.60 Sales Q/Q-90.60% Oper. Margin- RSI (14)49.38 Volatility5.39% 5.22%
OptionableYes Debt/Eq0.28 EPS Q/Q-159.90% Profit Margin- Rel Volume2.91 Prev Close1.23
ShortableYes LT Debt/Eq0.28 EarningsJul 29 AMC Payout- Avg Volume512.51K Price1.31
Recom1.70 SMA20-0.15% SMA50-2.99% SMA200-28.48% Volume1,492,843 Change6.50%
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Jul-12-17Upgrade Stifel Hold → Buy $1.25 → $3
Feb-28-17Resumed H.C. Wainwright Buy $3
Apr-25-16Initiated Rodman & Renshaw Buy $4
May-01-15Reiterated Stifel Buy $1.50 → $2.50
May-01-15Reiterated Cantor Fitzgerald Buy $2.50 → $3
Mar-25-13Initiated Stifel Buy $3
Nov-01-12Downgrade C.K. Cooper Buy → Hold $3
Aug-17-12Initiated C.K. Cooper Buy $3
Jun-23-09Initiated Caris & Company Buy $5
Mar-26-09Initiated Wedbush Morgan Hold
Sep-15-21 09:00AM  
Sep-07-21 09:00AM  
Aug-09-21 05:29AM  
Jul-29-21 07:25PM  
04:05PM  
Jul-22-21 08:30AM  
Jul-14-21 04:30PM  
Jun-25-21 09:37AM  
Jun-23-21 09:00AM  
Jun-09-21 09:00AM  
May-04-21 07:45PM  
04:05PM  
02:30PM  
Apr-27-21 08:30AM  
Mar-09-21 09:00AM  
Mar-04-21 05:31PM  
05:25PM  
02:30PM  
Mar-03-21 06:02PM  
Feb-04-21 09:18AM  
Feb-03-21 04:01PM  
Feb-02-21 08:28AM  
08:01AM  
Jan-25-21 08:30AM  
Jan-05-21 08:30AM  
Jan-04-21 08:30AM  
Dec-21-20 08:30AM  
Dec-16-20 08:30AM  
Dec-09-20 01:33PM  
Dec-07-20 11:15AM  
Nov-13-20 09:00AM  
Nov-10-20 08:30AM  
Nov-02-20 11:31PM  
06:15PM  
04:05PM  
04:02PM  
02:30PM  
07:35AM  
Oct-27-20 08:30AM  
Oct-26-20 04:30PM  
12:31PM  
Oct-05-20 08:30AM  
Sep-30-20 04:53PM  
Sep-23-20 08:30AM  
Sep-22-20 08:30AM  
Sep-10-20 08:30AM  
Aug-27-20 08:30AM  
Aug-26-20 04:30PM  
Aug-05-20 03:31PM  
08:30AM  
Aug-04-20 01:00AM  
Aug-03-20 06:35PM  
04:05PM  
Jul-28-20 08:30AM  
Jul-07-20 07:35AM  
Jul-01-20 08:30AM  
Jun-29-20 09:00AM  
08:30AM  
Jun-26-20 05:15PM  
10:37AM  
Jun-11-20 02:45PM  
May-28-20 09:00AM  
May-26-20 08:30AM  
May-20-20 10:04AM  
May-12-20 03:00PM  
02:20PM  
May-11-20 06:55PM  
04:05PM  
May-04-20 05:00PM  
Apr-28-20 12:33PM  
Mar-24-20 04:18PM  
Mar-03-20 04:05PM  
Feb-26-20 07:30AM  
Feb-10-20 08:05AM  
Jan-31-20 11:14AM  
Jan-17-20 08:19AM  
08:07AM  
06:45AM  
Jan-16-20 02:38PM  
07:24AM  
07:05AM  
Jan-02-20 05:28PM  
10:08AM  
09:00AM  
Dec-30-19 09:24AM  
Dec-29-19 09:40PM  
Dec-19-19 05:02PM  
Dec-05-19 03:21PM  
Nov-15-19 08:00AM  
Nov-12-19 08:45AM  
Nov-06-19 05:47PM  
Nov-04-19 04:05PM  
Oct-30-19 08:00AM  
Oct-21-19 10:12AM  
Oct-18-19 10:23AM  
Oct-17-19 04:05PM  
Oct-07-19 08:00AM  
Oct-02-19 08:00AM  
Sep-26-19 08:00AM  
Sep-18-19 07:39AM  
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Joice Judy RSr. VP Operations & Corp QAMay 14Option Exercise0.7660,13745,90794,969May 17 09:37 PM
Joice Judy RSr. VP Operations & Corp QAMay 14Sale1.7260,137103,68234,832May 17 09:37 PM